LAZOLE Capsule

ក្រុមហ៊ុនផលិតឱសថ:

 

WnsFelld, Pakistan

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    - ulcer of stomach and duodenum

    - erosive-ulcer stomach and duodenum involvements, connected with NSAID administration, stress ulcers

    - gastroesophageal reflux disease (GERD): curative treatment of reflux

    - esophagitis, symptomatic treatment of reflux-esophagitis

    - eradication of Helicobacter pylori (in combination with antibiotics)

    - pathological hypersecretory conditions, including Zollinger-Ellison syndrome

    - chronic gastritis with raised stomach acid-forming function in an exacerbation stage

    - non-ulcer dyspepsia.

    Dosage and Administration

    Lazole is used orally as a whole, not chewing, regardless of food intake.

    - Ulcer of stomach and duodenum: Prescribe 30mg/day. Course of treatment during exacerbation of duodenum ulcer is 2-4 weeks and for stomach ulcer 4-8 weeks.

    - Erosions or ulcers of stomach or duodenum, connected with NSAID administration: recommended dose is 30mg/day, course of treatment 4-8 weeks.

    - Prophylaxis of ulcer of stomach and duodenum at patients in risk group in connection with NSAID administration: 15mg/day till 12 weeks.

    - CORD (treatment of reflux-esophagitis): prescribe 30mg/day during 4-8 weeks; prolonged treatment up to 8 weeks, if necessary.

    - Symptomatic treatment of reflux-esophagitis: prescribe 15mg/day; course of treatment up to 8 weeks.

    - Maintenance therapy of reflux-esophagitis: 15mg/day; course of treatment up to 8 weeks; prolong the course of treatment up to 8 weeks, but not more than 12 weeks, if necessary.

    - Eradication of Helicobacter take 30mg 2 times per day in combination with antibiotics.

    - Pathological hypersecretory conditions, including Zollinger Ellison syndrome: initial dose of drug is 30mg 2 times per day, the dose is increased till 120mg/day. Course of treatment is determined individually.

    - Chronic gastritis with raised stomach acid-forming function in an exacerbation stage: prescribe 30mg 1-2 times per day. Course of treatment is 2-3 weeks.

    - Non-ulcer dyspepsia: prescribe 15-30mg 1-2 times per day. Course of treatment is 2-3 weeks.

    - At hepatic insufficiency and in patients of elderly age the treatment begins from half doses, gradually increases to recommended, but not more than 30mg/day.

  • ហាមប្រើ

    - hypersensitivity to drug components

    - malignant neoplasms in GIT

    - child and juvenile age till 18 years

    - first trimester of pregnancy, lactation period.

  • ផលរំខាន

    In gastrointestinal tract: diarrhea, increase or decrease of appetite, nausea, stomachache, constipation.

    In central system: headache, weakness, dizziness, sleepiness, depression, anxiety.

    Allergic reactions: skin eruption.

    Other: in single cases-influenza-like syndrome, myalgia.

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    First trimester of pregnancy, lactation period

    Contraindicated.

  • សកម្មភាពឱសថ

    Lazole is an antiulcer agent, specific proton pump inhibitor. Lansoprazole is metabolized in parietal stomach cells to active sulfonamide derivatives, which inactivate sulfhydric groups of H-1-K+-ATPase. This blocks the final step of hydrochloric acid production and leads to inhibition of basal and stimulated gastric hydrochloric acid secretion regardless of the stimulus nature. Lazole inhibits Helicobacter pylori growth and increases activity against Helicobacter pylori of other drugs.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp